Pages that link to "Q38798654"

The following pages link to The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus (Q38798654):

Displaying 21 items.

• Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials (Q33567077) (← links)
• Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. (Q38658251) (← links)
• Implications of the EMPA-REG Trial for Clinical Care and Research (Q38798623) (← links)
• Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials (Q38842559) (← links)
• SGLT2 Inhibitors: Benefit/Risk Balance (Q38931842) (← links)
• Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies (Q39500587) (← links)
• Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk? (Q39003573) (← links)
• Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. (Q39022309) (← links)
• Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes (Q39039079) (← links)
• Effect of diuretics on renal tubular transport of calcium and magnesium (Q39169297) (← links)
• Review article: effects of type 2 diabetes therapies on bone metabolism (Q42363966) (← links)
• Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus (Q47700645) (← links)
• Complex interplay among adiposity, insulin resistance and bone health (Q50044972) (← links)
• The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes. (Q53757094) (← links)
• SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists. (Q55411384) (← links)
• SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (Q61458485) (← links)
• Canagliflozin review – safety and efficacy profile in patients with T2DM (Q61803053) (← links)
• The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. (Q64916602) (← links)
• Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program (Q92535991) (← links)
• Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus (Q92925698) (← links)
• Diabetes pharmacotherapy and effects on the musculoskeletal system (Q93364919) (← links)